EMA panel backs EU approval of Roche’s Ocrevus for pediatric relapsing MS patients 10+

Bitget2026/09/18 10:45

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

EMA’s CHMP recommended EU approval of Roche’s Ocrevus IV for relapsing multiple sclerosis in patients aged 10 and older.
European Commission decision expected soon; FDA cleared the pediatric use in May 2026.
Phase III OPERETTA 2 showed non-inferior relapse control versus fingolimod; 48% lower relapse risk.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Roche Holding AG published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609180645OMX_____CNEWS_EN_GNW1001263433_en) on September 18, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

EMA panel backs EU approval of Roche’s Ocrevus for pediatric relapsing MS patients 10+

You may also like

Crypto prices